Upcoming ASH studies: Adcetris + AVD achieves 92% complete remission rate in front-line Hodgkin and strong response in non-Hodg
I traded back GM for SGEN today. The trade netted about $5 bucks, so it worked out. I still like GM also.
I plan to stick around now but I still think it may show some weakness mid year 2013, Hopefully from a higher level.
Still believe $100+ is in SGEN future.